Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $137 | $38 | $142 | $193 |
| Short-Term Investments | $176 | $58 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $3 | $2 | $2 |
| Total Curr. Assets | $316 | $99 | $144 | $195 |
| Property Plant & Equip (Net) | $18 | $16 | $17 | $14 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $2 | $2 |
| Total NC Assets | $20 | $17 | $19 | $16 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $336 | $116 | $163 | $211 |
| Liabilities | – | – | – | – |
| Payables | $1 | $0 | $1 | $1 |
| Short-Term Debt | $3 | $2 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $11 | $9 | $7 | $6 |
| Total Curr. Liab. | $15 | $11 | $9 | $8 |
| LT Debt | $9 | $11 | $12 | $11 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $1 | $0 | $0 | $0 |
| Total NC Liab. | $10 | $11 | $12 | $11 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $25 | $22 | $20 | $19 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$262 | -$451 | -$393 | -$333 |
| AOCI | $0 | -$0 | $0 | $0 |
| Other Equity | $573 | $545 | $536 | $524 |
| Total Equity | $310 | $94 | $143 | $191 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $336 | $116 | $163 | $211 |
| Net Debt | -$124 | -$26 | -$129 | -$180 |